Abingworth’s Verona Pharma VRNA Stock Holding History

Abingworth’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$64.2M	Hold	2,457,500	–	–	20.92%	2
2022 Q3	$25.1M	Hold	2,457,500	–	–	8.58%	5
2022 Q2	$10.2M	Buy	2,457,500 +1	+0%	+$4	3.26%	8
2022 Q1	$12.1M	Hold	2,457,499	–	–	3.44%	8
2021 Q4	$16.3M	Hold	2,457,499	–	–	3.95%	9
2021 Q3	$13.4M	Hold	2,457,499	–	–	3.04%	9
2021 Q2	$16M	Hold	2,457,499	–	–	4.95%	9
2021 Q1	$20.3M	Hold	2,457,499	–	–	7%	5
2020 Q4	$16.9M	Hold	2,457,499	–	–	5.79%	5
2020 Q3	$15.3M	Buy	2,457,499 +1,555,556	+172%	+$10.7M	3.28%	7
2020 Q2	$4.22M	Hold	901,943	–	–	1.18%	10
2020 Q1	$3.72M	Hold	901,943	–	–	2.47%	8
2019 Q4	$5.23M	Hold	901,943	–	–	2.53%	7
2019 Q3	$4.12M	Hold	901,943	–	–	2.61%	7
2019 Q2	$4.54M	Hold	901,943	–	–	1.74%	6
2019 Q1	$5.5M	Hold	901,943	–	–	4.92%	7
2018 Q4	$8.12M	Hold	901,943	–	–	7.38%	3
2018 Q3	$11.3M	Buy	+901,943	New	+$11.6M	6.7%	3

Other funds holding VRNA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Abingworth's VRNA Position: Q4 2022 in Review

Abingworth held its Verona Pharma (VRNA) position steady in Q4 2022 at 2,457,500 shares worth $64.2M. The position accounts for 20.92% of the portfolio, ranked #2.

Abingworth first reported a position in VRNA in Q3 2018 and has held it in 18 quarters since. 88 funds tracked by Wall St. Rank hold VRNA as of Q4 2022.

Abingworth held 2,457,500 shares of Verona Pharma worth $64.2M as of Q4 2022.
Abingworth left its Verona Pharma share count unchanged in Q4 2022.
Verona Pharma made up 20.92% of Abingworth's portfolio in Q4 2022, its #2 holding.
Abingworth first reported a position in Verona Pharma in Q3 2018 and has held it in 18 quarters since.
88 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.